High p62 and ALDH1A3 Reduce the Effectiveness of Endocrine Therapy in Luminal B Breast Cancer
Authors:
Open Access
- 1 November 2025
- journal article
- Published by International Institute of Anticancer Research in Cancer Diagnosis & Prognosis
- Vol. 5 (6) , 677-697
Abstract
Background/Aim: High expression of p62 and ALDH1A3 indicates a poor clinical outcome in luminal B breast cancer, and p62 is involved in the progression of ALDH1-positive luminal B breast cancer stem cells. However, the association between endocrine therapy and high p62 and ALDH1A3 expression, in luminal B breast cancer remains unclear. Materials and Methods: Two datasets with gene expression and clinical data for patients with primary breast cancer (METABRIC, n=2,509; The Cancer Genome Atlas, n=1,084) were downloaded and statistically analyzed. To evaluate the association between the p62 and ALDH1A3 expression levels and endocrine therapy, including tamoxifen and aromatase inhibitor, in patients with luminal B breast cancer, disease-specific survival was examined using Kaplan-Meier and multivariate Cox regression analyses. Results: Patients with p62high ALDH1A3high luminal B breast cancer treated with endocrine therapy exhibited a poor prognosis. Moreover, patients with p62high ALDH1A3high luminal B breast cancer treated with tamoxifen showed a trend towards a poor prognosis, but those treated with aromatase inhibitors showed a significantly poor prognosis. These results suggest that endocrine therapy, especially aromatase inhibitors, exhibits a reduced effectiveness against p62high ALDH1A3high luminal B tumors. Conclusion: p62 and ALDH1A3 could be used together as a prognostic biomarker for predicting the efficacy of endocrine therapy for luminal B breast cancer.Keywords
This publication has 74 references indexed in Scilit:
- ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical OutcomeCell Stem Cell, 2007
- p62/SQSTM1 Binds Directly to Atg8/LC3 to Facilitate Degradation of Ubiquitinated Protein Aggregates by AutophagyJournal of Biological Chemistry, 2007
- Cytosolic overexpression of p62 sequestosome 1 in neoplastic prostate tissueHistopathology, 2005
- p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell deathJournal of Cell Biology, 2005
- p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cellsOncogene, 2003
- Stem cells, cancer, and cancer stem cellsNature, 2001
- The atypical PKC‐interacting protein p62 channels NF‐κB activation by the IL‐1–TRAF6 pathwayThe EMBO Journal, 2000
- The interaction of p62 with RIP links the atypical PKCs to NF‐κB activationThe EMBO Journal, 1999
- Localization of Atypical Protein Kinase C Isoforms into Lysosome-Targeted Endosomes through Interaction with p62Molecular and Cellular Biology, 1998
- Interaction of protein kinase C ζ with ZIP, a novel protein kinase C-binding proteinProceedings of the National Academy of Sciences, 1997